Tumor specific vaccination therapy for advanced/recurrent cervical cancer using HLA-A*2402 restricted Specific Epitope Peptides Cocktail derived from Tumor genom/Tumor related Angiogenetic factors genom
Phase 1
- Conditions
- advanced/recurrent cervical cancer with the conditions of unremoval by surgery, or refractory, chemo-resistant disease.
- Registration Number
- JPRN-UMIN000003902
- Lead Sponsor
- Iwate Medical University School of Medicine department of Obstetrics and Gynecology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. pregnant women 2. breast feeding mothor(stop brest feeding) 3.women who are willing to be pregnant(must perform contraception) 4.complication of uncontrolable infection 5.Usage of continual systemic steroid and immuno-suppressant is prohibited during treatment. 6. Who are recognized ineligible by the resiponsible investigator or investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method